Dynamic Changes of Tim-3 on Monocytes and Soluble Tim-3 in Patients With Sepsis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-12-31

Study Completion Date

2015-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In this study, the investigators will dynamically detect the expression of an immune regulator- T cell Ig and mucin domain protein 3 (Tim-3) in patient with sepsis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Expression of TIM-3 on Lymphocytes in Sepsis

NCT02319876

Sepsis Immunosuppression

UNKNOWN

Detection Of Monocytes/Macrophages Function And Tim-3 Expression In Septic Patients

NCT01801839

Sepsis SIRS(Systemic Inflammatory Response Syndrome)

COMPLETED

Co-inhibitory Molecules on Treg and miR-155-5p in Patients With Sepsis

NCT05126537

28 Day Mortality

UNKNOWN

Dynamic Alterations of Th2/Th1 With New Onset of Community-acquired Severe Sepsis Patients

NCT02883218

Sepsis

COMPLETED

The Efficacy and Safety of Ta1 for Sepsis

NCT02867267

Sepsis

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In this study, we will collect the peripheral blood of 1,3,5,7,10,14 day after diagnose of sepsis.All the patients rolled in this study will be divided into three groups which is sepsis, severe sepsis and septic shock group according their severity. Then,the flow cytometry will be used to detect the express of Tim-3 on monocyte and ELISA will be used to exam the plasm soluble Tim-3.IL-6,IL-10,IL-12 and TNF-αin the peripheral blood will also be detected. We would like to find a new marker to predict the severity and prognosis of sepsis patients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sepsis Severe Sepsis Septic Shock

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

normal control

healthy people

No interventions assigned to this group

sepsis

mild response to infection

No interventions assigned to this group

severe sepsis

infection with at least one organ dysfunction

No interventions assigned to this group

septic shock

patients with septic shock

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* More than one of the following:

clinical manifestations: (1) a body temperature greater than 38℃ or less than 36℃; (2) a heart rate greater than 90 beats/minute; (3)tachypnea, manifested by a respiratory rate greater than 20 breaths per minute, or hyperventilation, as indicated by a PaCO2 of less than 32 mmHg; and (4)an alteration in the white blood cell count, such as a count greater than 12×10\^9/L, a count less than 4×10\^9/L, or the presence of more than 10 percent immature neutrophils

Exclusion Criteria

* (1)patients younger than 18 years of age; (2)agranulocytosis (granulocyte counts,0.5×10\^9/L); (3) those discharged within 24 h; (4) those diagnosed with HIV infection or cancer; and (5) patients who refused to participate.

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes